Pre-clinical studies investigated gene correction in hereditary pulmonary alveolar proteinosis with CSF2RA mutations [38] and in surfactant protein B deficiency [39], while stem cells have been used to correct pulmonary alveolar proteinosis in CSF2RB deficient mice models [40]. This evidence concerns the gene CSF2RA and pulmonary alveolar proteinosis.